It’s ASCO time again. The annual meeting of the American Society of Clinical Oncology (ASCO) is now just over a week away, with the event due to start in Chicag 22 May 2019
In a previous incarnation, Boehringer Ingelheim chief financial officer Michael Schmelmer spearheaded a bold approach to innovation which could bear digital fru 10 May 2019
Thankfully, the growing anti-microbial resistance (AMR) crisis is now getting some major headlines and airtime, so that even many lay people are getting a good 2 May 2019
The Pharmaceutical Price Regulation Scheme (PPRS) is dead; long live the Voluntary Scheme for Branded Medicines Pricing and Access (Voluntary Scheme)! 16 April 2019
Judging which companies are topping the oncology research charts in any given quarter or year can be highly subjective, but sometimes drugmakers present a serie 22 March 2019
Research shows some 79% of the American public view the cost of prescription drugs as unreasonable, and lawmakers and regulators are increasingly convinced the 8 March 2019
“Everyone in the ecosystem recognises that there's going to a lot of innovations coming forward in the next years and those need to get to patients.” 3 March 2019
With a matter of weeks to go until the UK is due to leave the European Union, negotiations between warring factions in the British political establishment threa 15 February 2019
Pipelines are the future of pharma, providing an indication of which patients, companies and shareholders will benefit from the next generation of cures and tre 24 January 2019
Predicting a year in pharma is difficult at the best of times, but in an era of enormous uncertainty – with politics in established markets as impulsive as it i 20 December 2018
Given that copycat biologics are a relatively new part of the healthcare landscape, especially in the USA, the blueprint on how to become a successful biosimila 14 December 2018
Drug-making is sometimes pictured as one of the last surviving “traditional” industries, successfully resisting waves of change that have overtaken other busine 5 December 2018
In recent decades, the pharmaceutical industry has developed next-generation treatments for cystic fibrosis (CF) that have a real impact on patients’ lives and 23 November 2018
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.